Edition:
United States

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

54.94USD
20 Apr 2018
Change (% chg)

$-0.22 (-0.40%)
Prev Close
$55.16
Open
$55.15
Day's High
$55.70
Day's Low
$54.25
Volume
47,980
Avg. Vol
98,096
52-wk High
$97.14
52-wk Low
$45.05

Select another date:

Mon, Apr 16 2018

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing‍​

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2En48mt) Further company coverage:

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2AG5uGB) Further company coverage:

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Oct 27 Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

Select another date: